Capitalize on Breakthrough Therapy Designation Shifts: Benchmark Pfizer, Roche, Novartis, Merck and AstraZeneca to Accelerate Approvals, Defend Pipeline ROI and Capture Revenue

Expedited FDA pathways are boosting oncology and rare-disease drug development, with gene therapy, immunotherapy and precision medicine creating key opportunities.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Breakthrough Therapy (BT) Designation - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Breakthrough Therapy (BT) Designation was estimated at US$79.7 Billion in 2025 and is projected to reach US$212.5 Billion by 2032, growing at a C